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Imaging the development of 
chronic Chagas disease after oral 
transmission
Michael D. Lewis, Amanda F. Francisco, Shiromani Jayawardhana, Harry Langston, 
Martin C. Taylor  & John M. Kelly  
Chagas disease is a zoonosis caused by the protozoan parasite Trypanosoma cruzi. Transmission cycles 
are maintained by haematophagous triatomine bug vectors that carry infective T. cruzi in their faeces. 
Most human infections are acquired by contamination of mucosal membranes with triatomine faeces 
after being bitten, however, T. cruzi can be transmitted by several other routes. Oral transmission is 
an increasingly important aspect of Chagas disease epidemiology, typically involving food or drink 
products contaminated with triatomines. This has recently caused numerous outbreaks and been 
linked to unusually severe acute infections. The long-term impact of oral transmission on infection 
dynamics and disease pathogenesis is unclear. We used highly sensitive bioluminescence imaging and 
quantitative histopathology to study orally transmitted T. cruzi infections in mice. Both metacyclic and 
bloodform trypomastigotes were infectious via the oral cavity, but only metacyclics led to established 
infections by intra-gastric gavage. Mice displayed only mild acute symptoms but later developed 
significantly increased myocardial collagen content (p = 0.017), indicative of fibrosis. Gastrointestinal 
tissues and skin were the principal chronic infection reservoirs. Chronic phase parasite load profiles, 
tissue distribution and myocardial fibrosis severity were comparable to needle-injected controls. Thus, 
the oral route neither exacerbates nor ameliorates experimental Chagas disease.
Chagas disease (American trypanosomiasis) is caused by infection with Trypanosoma cruzi, a protozoan parasite. 
Approximately 6 million people are infected and the disease causes ~13,000 deaths annually and a large morbidity 
burden in affected populations1. Chagas disease is endemic in most of Latin America and is becoming an increas-
ingly important global public health problem as a result of migration2,3. T. cruzi has a complex life cycle4,5, as 
part of which it is transmitted between mammalian hosts, including humans, by blood-feeding triatomine bugs. 
Epimastigote parasites replicate in the insect’s midgut before migrating to the hindgut, where they can transform 
into non-dividing metacyclic trypomastigotes (MTs), which are infectious to mammals. When a triatomine takes 
a blood meal it frequently deposits faeces containing MTs onto its host. Thereafter, the MT parasites can contami-
nate the bite site or mucosal tissues, leading to infection. MTs actively invade host cells and transform into a third 
developmental form, the amastigote, which replicates in the host cell cytosol. After several rounds of replication, 
amastigotes make a developmental transition resulting in bloodstream trypomastigotes (BTs), which can either 
invade a new host cell, or complete the life cycle by transforming into epimastigotes if they are taken up by a tri-
atomine bug as part of a blood meal.
Control programs have successfully reduced or interrupted vectorial transmission in many regions6,7. One 
consequence of this is a renewed focus on other sources of infection, including the congenital route and trans-
mission from donors to transplant or transfusion recipients. The oral transmission route has garnered particular 
attention, not least because of recurring outbreaks involving parasite-contaminated food and drink products8–15. 
The number of acute Chagas disease cases attributed to oral infection has increased dramatically since 20001,16. It 
is not clear whether this trend reflects better surveillance or genuine changes in transmission patterns driven by 
eco-epidemiological factors. The oral route is also important because consumption of triatomines by wild mam-
mals is a key part of natural T. cruzi transmission cycles17. Oral vaccination of domesticated animal reservoirs, e.g. 
dogs, is also envisaged as a potentially valuable disease control measure18.
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The effect that transmission routes have on Chagas disease clinical outcomes is poorly understood. Vector 
transmitted infections are rarely diagnosed in the acute phase and even amongst those that are, the symptoms 
are generally mild, with fewer than 5% proving fatal; the remainder progress to life-long chronic infections19. In 
contrast, some oral outbreaks have been associated with unusually severe symptoms and high fatality rates, often 
>20%16, raising concerns that oral transmission is particularly dangerous. Experimental studies have reproduced 
features of severe acute Chagas disease in mice after oral inoculation20,21.
It is not known whether reports of increased severity of orally-acquired infections can be explained by the route 
of parasite entry or other co-varying factors. Furthermore, the longer term impact of oral transmission on chronic 
disease progression and severity has not been studied. We recently developed an enhanced sensitivity real-time 
imaging method to assess chronic T. cruzi infections22,23, which has enabled us to address these questions.
Results
Oral transmission efficiency and course of infection. We used a high sensitivity T. cruzi in vivo imag-
ing model to track infections in mice after inoculation of parasites via intra-peritoneal (i.p.) injection, intra-gas-
tric gavage, or buccal deposition (Table 1). Gavage of MTs, the infectious form present in insect vectors, led to 
established infections in 25% of mice (n = 16), compared to 92% in the needle-injected controls (n = 13). The MT 
inoculum was not transmissible via the oral cavity (n = 6). When the number of parasites in the inoculum was 
increased from 104 to 105, infectivity was boosted to 67% via gavage (n = 3) and 100% via oral cavity (n = 3). We 
were unable to infect mice with BTs via the stomach (n = 10). However, buccal inoculation of BTs led to estab-
lished infections in 36% of mice (n = 11), compared to 100% in the needle-injected controls (n = 13). There were 
no fulminant infections and no disparities between animals infected via different routes with respect to weight, 
body condition or activity.
Serial bioluminescence imaging (Fig. 1) showed that those mice that did acquire orally-transmitted T. cruzi 
infections initially had lower average parasite loads compared to the needle-injected controls. The parasite load 
at the acute peak of infection, 14–21 days post-infection (dpi), was systemically distributed and quantitatively 
similar in all groups except the MTs intra-gastric gavage cohort, in which it was significantly lower than the i.p. 
injection controls (one way ANOVA, p = 0.01). The immune-mediated clearance phase proceeded similarly in all 
groups, involving an approximately 100-fold parasite load reduction by 56 dpi. Thereafter, chronic infections were 
characterised by spatiotemporally dynamic bioluminescent foci, with parasite loads fluctuating around similar 
means. Heart weights did not vary significantly between groups, but spleen weights were significantly, and equiv-
alently increased in all infected groups, apart from the BT intra-gastric gavage cohort, in which no infections were 
established (Fig. 2).
We conclude that oral transmission of the TcVI-CL Brener T. cruzi strain is relatively inefficient. When infec-
tions are established, there are reduced parasite loads in the early acute stage, but the long-term infection dynam-
ics are equivalent to needle-injected controls.
Tissue tropism after oral transmission. During the acute infection phase, T. cruzi is able to parasitize 
highly diverse cell types and tissues24, but the actual distribution of parasites could be affected by the route of 
entry. We therefore tested the hypothesis that parasite distribution is affected by the transmission route. To estab-
lish the early targets of T. cruzi infection, organs and tissues were excised and imaged at 6 dpi (Fig. 3). Mice that 
were needle-injected with either MTs or BTs already had broadly disseminated infections by this time-point, 
with the spleen, GI tract and adipose-rich tissues having the highest parasite loads. In mice that received MTs by 
intra-gastric gavage, parasites were only detected in the stomach. Infections were undetectable in any organ/tissue 
from animals inoculated via the oral cavity with BTs or MTs, suggesting that very few parasites in the inoculum 
were productively transmitted.
To establish the long-term reservoirs of T. cruzi infection in the chronic phase, organs and tissues were excised 
and imaged at 4 months post-infection (Fig. 4 and Supplementary Fig. 1). Consistent with the in vivo imaging 
data, mice that were gavaged with BTs showed no evidence of infection in any tissues. In all other experimental 
Trypomastigote type Route Dose Inoculated (n) Infected (n) Infectivity (%)
Metacyclic Needle (i.p.)a 1 × 104 13 12 92.3
Metacyclic Oral (g)b 1 × 104 16 4 25.0
Metacyclic Oral (g)b 1 × 105 3 2 66.7
Metacyclic Oral (g)b Eitherd 19 6 31.6
Metacyclic Oral (b)c 1 × 104 6 0 0.0
Metacyclic Oral (b)c 1 × 105 3 3 100
Metacyclic Oral (b)c Either d 9 3 33.3
Blood Needle (i.p.)a 1 × 104 13 13 100
Blood Oral (g)b 1 × 104 10 0 0.0
Blood Oral (b)c 1 × 104 11 4 36.4
Blood Oral (b)c 1 × 105 3 0 0.0
Blood Oral (b)c Eitherd 14 4 28.6
Table 1. Infectivity of Trypansoma cruzi in mice by oral routes. aIntra-peritoneal; bintra-gastric gavage; cbuccal 
administration; d1 × 104 and 1 × 105 data combined.
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groups, the primary sites of chronic parasite persistence were the large intestine, stomach, GI mesenteries and 
the skin. Other notable sites that were T. cruzi positive in only a minority of animals included lung, adipose 
and peritoneum. The level of dissemination in chronic infections, gauged by calculating the number of parasite 
positive sites per animal, was higher on average after oral transmission than after i.p. injection, although this was 
not statistically significant (Supplementary Fig. 2). Otherwise, the chronic tissue distributions in orally infected 
animals were broadly comparable with needle-injected controls (Fig. 4b).
Cardiac pathology after oral transmission. Fibrosis of the myocardium is central to the pathogenesis of 
cardiac Chagas disease25,26. We used quantitative histopathological analysis of myocardial collagen content and 
found a significant increase in mice that had been infected via the oral route compared to uninfected animals 
(Fig. 5). The needle-injected controls also had significant fibrosis. There was no significant difference in severity 
between the oral infection and needle-injection cohorts. The extent of myocardial fibrosis in these animals was also 
similar to our findings for subcutaneously injected mice23. We conclude that orally acquired T. cruzi infection causes 
chronic cardiomyopathy, although this route of transmission does not exacerbate the condition in this model.
Figure 1. Serial evaluation of T. cruzi infection after oral transmission by in vivo bioluminescence imaging. 
(a) Serial ventral images of individual mice infected with blood or metacyclic trypomastigotes mouse via oral 
routes or needle injection (n = 6–16). Log-scale pseudocolour heat-maps show intensity of bioluminescence; 
minimum and maximum radiances are indicated. (b) Charts show mean bioluminescence ± SEM for mice 
from the experiment represented by images in (a) and non-infected control mice (n = 10) to show background 
luminescence. Mice that were inoculated with T. cruzi but did not develop an infection were excluded, including 
the entire intra-gastric blood trypomastigote gavage cohort.
Figure 2. Heart and spleen weights in mice chronically infected with T. cruzi after oral transmission. Mice were 
infected with either metacyclic or bloodstream T. cruzi trypomastigotes (MT, BT) by i.p. injection, oral gavage 
(g) into the stomach or deposition in the oral cavity (b). Hearts (a) and spleens (b) from mice in which chronic 
infections were established were weighed at necropsy 4 months post-infection.
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Discussion
Trypanosoma cruzi is unusual, though not unique, amongst protozoan parasites in its ability to establish a sys-
temic infection in its host after transmission via an oral route27. Most human cases involve drinks contaminated 
with insect-derived MTs16,17, which express a surface glycoprotein (gp82) that binds gastric mucin and facilitates 
invasion of the gastric mucosa28,29. Consistent with this, our infection imaging experiments showed that early 
acute infection was confined to the stomach. Deposition of MTs in the mouse oral cavity also caused infection, 
but this required a higher inoculum. Comparison with previous work using the Tula T. cruzi strain30 indicates that 
the oral MT infectivity of the CL Brener strain is comparatively low, even though both strains belong to the same 
genetic lineage (TcVI). Experimental studies suggest there are genetic factors that influence oral infectivity31. 
Nevertheless, most of the major T. cruzi subgroups are implicated in human oral Chagas disease cases14,32–35, so 
variability of these putative determinants can be expected to occur at the level of individual strains.
Oral transmission involving mammalian stage parasites (BTs and amastigotes) is rarely studied. A few cases 
of acute infection linked to consumption of infected meat from animal reservoirs have been reported36 and car-
nivory is a component of sylvatic transmission cycles37. In our experiments, BTs were not transmissible via the 
stomach. Unlike MTs, these forms are not adapted for low pH environments and do not express gp8238. Hoft30 
reported a single mouse (from a total of five) that became infected after buccal inoculation with Tula strain BTs, 
but concluded this was probably an artefact related to mucosal tissue damage or disease. Our finding that infec-
tion occurred in 36% of healthy animals after buccal inoculation of CL Brener strain BTs shows that these parasite 
forms are infectious via this route, with a transmission efficiency comparable to MTs. A recent imaging study 
showed that naso-maxillary tissues are the main site of early parasite replication after buccal infection with tissue 
culture derived trypomastigotes (TCTs)39. In our ex vivo tissue analysis at the comparable time point (6 dpi), the 
infections in both the MT and BT buccal transmission groups were below the limit of detection. Differences in 
parameters such as inoculum size or parasite strain could explain this disparity, or it may reflect intrinsic differ-
ences between BTs and TCTs.
Tracking the long-term infection dynamics of chronic T. cruzi infections and establishing their impact on 
Chagas disease has only recently become possible, through the development of sufficiently sensitive imaging 
models24. We observed that over a four month course of infection, bioluminescence-inferred parasite loads in 
orally infected mice were very similar to those in needle-injected controls. The only notable exception was the 
early acute phase, 1–2 weeks post-infection, when parasite loads were lower and much less disseminated. There 
were no mortalities and acute symptoms were mild, generic and similar between oral and needle-injected groups. 
Therefore, the high mortality rates in human oral transmission cases16 are likely to be better explained by factors 
such as inoculum size, parasite genetics and lack of previous exposure to T. cruzi than the route of parasite entry.
The large intestine, stomach, GI mesenteric tissue and skin were the main sites of chronic parasite persistence 
after oral infection. These are the same sites we had previously identified for mice that were infected via i.p., i.v. 
and s.c. injection routes22,23. However, this is the first demonstration that these tissues act as infection reservoirs 
after transmission by a natural route that has caused high numbers of human infections. Persistence in the stom-
ach after intra-gastric invasion indicates that primary exposure of the host to T. cruzi antigens in mucosal sites 
generates neither localised protective immunity, nor enhanced tolerance to infection. This is consistent with data 
Figure 3. Ex vivo tissue bioluminescence imaging of mice acutely infected with T. cruzi after oral transmission. 
Mice were infected with 105 metacyclic or bloodstream T. cruzi trypomastigotes (MT, BT) by i.p. injection, 
oral gavage [p.o. (g)] into the stomach or deposition in the oral cavity [p.o. (b)]. Parasite distribution was 
assessed by bioluminescence signal in organs and tissue samples from mice at 6 days post-infection. Log-scale 
pseudocolour heat-maps show intensity of bioluminescence; minimum and maximum radiances are indicated. 
Samples were arranged as indicated in the table. Images are representative of three independent replicates with 
the table showing the overall assessment of T. cruzi presence vs. absence in each sample.
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showing oral infection generates broadly similar mucosal and systemic CD8+ T cell responses to i.p. or s.c. injec-
tions, and does not preferentially induce a “gut-homing” T cell phenotype18.
Repeated cycles of inflammation and tissue repair in the heart tissue of hosts with chronic T. cruzi infection 
leads to cardiac fibrosis, which is central to the pathogenesis of Chagas cardiomyopathy24–26. We found that orally 
infected mice developed cardiac fibrosis of a similar severity to needle-injected controls. Therefore, mucosal 
transmission does not result in long-term host-parasite interaction dynamics that are specifically more or less 
pathogenic than non-mucosal transmission. This has potential implications for management of chronic Chagas 
disease patients and the design of oral anti-T. cruzi vaccines.
Methods
Parasites, mice and infections. T. cruzi CL Brener (TcVI) constitutively expressing the red-shifted firefly 
luciferase PpyRE9h23 were used in all experiments. Infectious metacyclic trypomastigotes (MTs) and blood trypo-
mastigotes (BTs) were generated as previously described23. Female BALB/c mice aged 8–12 weeks were infected 
with 104 or 105 BTs or MTs by i.p. injection of 0.2 mL, oral gavage into the stomach (intra-gastric route) of 0.2 mL, 
or deposition in the oral cavity using a pipette (buccal route) of 20 µL. Animal work was approved by the LSHTM 
Animal Welfare and Ethical Review Board and carried out under UK Home Office project licence (PPLs 70/6997 
and 70/8207) in accordance with the UK Animals (Scientific Procedures) Act. BALB/c mice were purchased from 
Charles River (UK) and maintained under specific pathogen-free conditions in individually ventilated cages, with 
a 12 hour light/dark cycle and ad libitum food and water.
Figure 4. Tissue parasite distribution in mice chronically infected with T. cruzi after oral transmission. (a) 
Representative ex vivo images of tissue-specific parasite bioluminescence at 4 months post-infection. Images 
show infection distributions and intensities for adipose, gut mesenteric tissue, heart, lung, large intestine, liver, 
skeletal muscle, spleen, small intestine and stomach. Log-scale pseudocolour heat-maps show intensity of 
bioluminescence; minimum and maximum radiances are indicated. Tissues and organs are arranged as shown 
(bottom right). (b) Charts show the proportion of animals that had above threshold bioluminescence in the 
indicated organs and tissue samples. The category “Other” refers to bioluminescence signals in the animal 
carcass that could not be unambiguously assigned to a specific organ. MT oral (intra-gastric) n = 6, MT i.p. 
n = 12, BT oral (buccal) n = 4, BT i.p. n = 12.
www.nature.com/scientificreports/
6ScIenTIFIc REPORTS |  (2018) 8:11292  | DOI:10.1038/s41598-018-29564-7
Bioluminescence imaging. Mice were injected with 150 mg/kg d-luciferin i.p., then anaesthetized using 
2.5% (v/v) gaseous isoflurane in oxygen. To measure bioluminescence, mice were placed in an IVIS Lumina II 
system (Caliper Life Science) and images were acquired 10–20 minutes after d-luciferin administration using 
LivingImage 4.3. Exposure times varied between 30 seconds and 5 minutes, depending on signal intensity. After 
imaging, mice were revived and returned to cages. For ex vivo imaging, mice were injected with 150 mg/kg 
d-luciferin i.p., then sacrificed by ex-sanguination under terminal anaesthesia 7 minutes later. Mice were perfused 
with 10 mL 0.3 mg/mL d-luciferin in PBS via the heart. Organs and tissues were transferred to culture dishes, 
soaked in 0.3 mg/mL d-luciferin in PBS, and then imaged in the IVIS system.
To estimate parasite burden in live mice, regions of interest (ROIs) were drawn using LivingImage v.4.3 to 
quantify bioluminescence expressed as total flux (photons/second) summed from dorsal and ventral images. The 
Figure 5. Cardiac fibrosis in mice chronically infected with T. cruzi after oral transmission. (a) Representative 
myocardial sections stained with picro-sirius red, magnification 400X and 100X , scale bar = 100 µm. (b) 
Quantification of collagen content (% red area in stained sections) as a marker of cardiac fibrosis severity. Data 
are the means ± SEM, pooled from three experiments. Not infected n = 12, MT oral n = 5, MT i.p. n = 12, BT 
i.p. n = 8. Asterisks indicate p-values for comparisons with the not infected control group in a one-way ANOVA 
test (*p < 0.05; ***p < 0.001).
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detection threshold for in vivo imaging was determined using control uninfected mice. Ex vivo images of tissues 
and organs were scored for the presence of T. cruzi using a detection threshold for infection foci of at least 10 
contiguous bioluminescent pixels of radiance ≥3 × 103 photons/second/cm2/sr. These criteria were established 
by reference to uninfected control animals.
Histopathology. Heart samples were fixed in GlyoFixx (Thermo Scientific) for 24–72 hours, then dehy-
drated, cleared, and embedded in paraffin. Three micron sections were stained with haematoxylin for 8 minutes, 
followed by picro-sirius red for 1 hour, then dehydrated and mounted with DPX. Ten 400X magnification images 
of randomly selected fields covering the ventricular and atrial regions were taken on a Leica DM3000 microscope 
for quantitative histomorphometric analysis. The base of the heart and major vessels were excluded due to high 
inherent collagen content. A fibrosis index was derived by automated quantification of the proportion of tissue 
staining positive for collagen (red pixels), using Leica Application Suite v4.5.0. An increase in collagen content 
compared to uninfected controls was considered indicative of myocardial fibrosis.
Statistics. Individual animals were used as the unit of analysis. Groups were compared using Student’s t-test 
or one-way ANOVA, with Tukey’s post-hoc correction in GraphPad Prism v.7.
Data availability. Materials, data and associated protocols are available on request.
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